**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 

**Drugbank DB00277** Drugbank DB00277 https://www.drugbank.ca/drugs/DB00277

PK-Sim Ontogeny Database Version 7.3 (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf) 

**Yun 2019** Yun, Y.E. and A.N. Edginton, Model qualification of the PK-SimÂ® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. Journal of Toxicology and Environmental Health, Part A, 2019: p. 1-26.

**Steinijans 1987** Steinijans, V.W., et al., Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. Eur J Clin Pharmacol, 1987. 33(5): p. 523-6.

**Gisclon 1997** Gisclon, L.G., et al., Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. The Journal of Clinical Pharmacology, 1997. 37(8): p. 744-750.

**Simons 1979** Simons, K.J., et al., Theophylline protein binding in humans. J Pharm Sci, 1979. 68(2): p. 252-3.